ATR and neoplasm: Drug screening did not reveal sensitivity to doxorubicin, platinum drugs, PARP inhibitors, or ATR inhibitors, suggesting these mutations in the context of this patient’s tumor biology and genetic landscape, did not confer sensitivity to these DNA damaging or DNA damage response (DDR) targeting drugs.